Open AccessSafety of Antiretroviral Prophylaxis of Perinatal Transmission for HIV-Infected Pregnant Women and Their Infants
Author(s) -
Lynne M. Mofenson,
Paula Munderi
Publication year - 2002
Publication title -
journal of acquired immune deficiency syndromes
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.162
H-Index - 157
eISSN - 1944-7884
pISSN - 1525-4135
DOI - 10.1097/00042560-200206010-00010
Subject(s) - medicine , transmission (telecommunications) , antiretroviral therapy , pediatrics , pregnancy , developing country , in utero , antiretroviral treatment , human immunodeficiency virus (hiv) , intensive care medicine , immunology , obstetrics , viral load , fetus , biology , ecology , electrical engineering , genetics , engineering
Worldwide, more than 1600 infants become infected with HIV each day. Almost all infections are a result of mother-to-child transmission of HIV, with most of these infections occurring in resource-poor countries. In developed countries, antiretroviral prophylaxis has dramatically reduced perinatal transmission to <2%. The potential now exists to extend this success to resource-poor countries using effective but shorter and less expensive antiretroviral regimens. With the potential widespread use of antiretroviral therapy for perinatal HIV prevention in resource-limited settings, there will be exposure of increasing numbers of infants to in utero and postpartum antiretroviral drugs for which long-term toxicity data is unknown. This article focuses on a review of what is known about safety of antiretroviral regimens used to interrupt mother-to-child transmission for women and their children.